Related Tags >> Genentech FDA Phase III Roche

Avastin News

Most Popular Avastin Story

MAbs are hottest segment of biotech industry

October 12, 2007 — 6:59am ET

Looking for the hottest segment of the biotech industry? Then take a look at monoclonal antibodies (mAbs). A new Datamonitor report projects 14 percent annual growth in the market for the antibody... Read more...

Avastin Press Releases

FDA Advisory Committee Unanimously Recommends Accelerated Approval of Genentech's Avastin for Previously Treated Brain Cancer
FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)
Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
New phase III study of Avastin in advanced breast cancer meets its primary endpoint of extending progression-free survival

Latest Headlines

Roche readies cancer data for ASCO
May 19, 2009
Roche dealt setback as Avastin misses trial goal
April 22, 2009
Roche CEO: Emphasizing drugs for primary care
July 2, 2008
ALSO NOTED: Genta places notes;Vaccine research blasts off; and much more...
June 6, 2008
SPOTLIGHT: Avastin leaves ASCO ahead of Erbitux
June 3, 2008
Kennedy's surgery may be followed by experimental therapy
June 2, 2008
A deluge of pre-ASCO data hits the market
May 16, 2008
Antisoma buys Xanthus for $52M
May 16, 2008
ALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...
May 14, 2008
Avastin, Erbitux battle for lung cancer market
April 21, 2008
Experts debate FDA signals on cancer drug approval
March 4, 2008
AstraZeneca's Recentin fails lung cancer trial
February 27, 2008
ALSO NOTED: Avastin approval may lower FDA bar; GTX shares skyrocket on cancer data; Novartis wins approval; and much more...
February 25, 2008
Genentech awaits Avastin decision
February 22, 2008
Genentech faces crucial Avastin decision
February 19, 2008
Genentech's blistering growth starts to cool
January 15, 2008
ALSO NOTED: FDA nixes Avastin for breast cancer; P&G reveals Phase II UC data;and much more...
December 6, 2007
Antisoma shares tank on bold new trial strategy
November 20, 2007
ALSO NOTED: Avastin delivers promising data for brain cancer; Genelabs regains development rights; and much more...
November 19, 2007
ALSO NOTED: Lilly grabs rights to pain therapy; Study outlines billions in potential R&D savings; Takeda shares hit by FDA move
October 30, 2007

Paid Research Reports

More Research Reports >>